A Randomized, Blinded, Placebo-Controlled, Single- and Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB033 in Healthy Japanese Subjects

Trial Profile

A Randomized, Blinded, Placebo-Controlled, Single- and Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB033 in Healthy Japanese Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Oct 2016

At a glance

  • Drugs Opicinumab (Primary)
  • Indications Multiple sclerosis; Optic neuritis
  • Focus Adverse reactions
  • Sponsors Biogen
  • Most Recent Events

    • 07 Oct 2016 Status changed from active, no longer recruiting to completed.
    • 05 Jul 2016 Status changed from recruiting to active, no longer recruiting.
    • 25 Feb 2016 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top